Narcolepsy - Pipeline Review, H1 2017

Date: May 9, 2017
Pages: 73
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until June 2, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NF8C48075DAEN
Leaflet:

Download PDF Leaflet

Narcolepsy - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2017, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 3, 2, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Avadel Pharmaceuticals Plc
Bioprojet SCR
Evotec AG
H.A.C. Pharma
Heptares Therapeutics Ltd
Jazz Pharmaceuticals Plc
Ono Pharmaceutical Co Ltd
OptiNose US Inc
Reset Therapeutics Inc
Sanofi
SK Biopharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Theranexus SAS
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LGD-3437 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-110068 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-N05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Apr 26, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness
Apr 24, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy
Mar 15, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Feb 13, 2017: Lincoln Medical's Wakix Rejects For Use Within NHS Scotland
Jan 25, 2017: A New Study Published by The Lancet Neurology Shows Efficacy of Pitolisant (Wakix) on Cataplexy in Patients with Narcolepsy
Dec 16, 2016: Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy
Nov 28, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy
Oct 27, 2016: Inclusion of the First Patient in the Phase II Clinical Study That Aims to Test THN102 in Patients Affected by Narcolepsy
Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218
Oct 04, 2016: Theranexus Has Obtained an Orphan Drug Designation from the FDA for THN102 in the Treatment of Narcolepsy
Jul 11, 2016: Mazindol Granted Orphan Drug Designation in the US & Europe for Treatment of Narcolepsy
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness
Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Narcolepsy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H1 2017
Narcolepsy - Pipeline by Bioprojet SCR, H1 2017
Narcolepsy - Pipeline by Evotec AG, H1 2017
Narcolepsy - Pipeline by H.A.C. Pharma, H1 2017
Narcolepsy - Pipeline by Heptares Therapeutics Ltd, H1 2017
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2017
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Narcolepsy - Pipeline by OptiNose US Inc, H1 2017
Narcolepsy - Pipeline by Reset Therapeutics Inc, H1 2017
Narcolepsy - Pipeline by Sanofi, H1 2017
Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
Narcolepsy - Pipeline by Theranexus SAS, H1 2017
Narcolepsy - Dormant Projects, H1 2017
Narcolepsy - Discontinued Products, H1 2017

LIST OF FIGURES

Number of Products under Development for Narcolepsy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Avadel Pharmaceuticals Plc
Bioprojet SCR
Evotec AG
H.A.C. Pharma
Heptares Therapeutics Ltd
Jazz Pharmaceuticals Plc
Ono Pharmaceutical Co Ltd
OptiNose US Inc
Reset Therapeutics Inc
Sanofi
SK Biopharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Theranexus SAS
Skip to top


Ask Your Question

Narcolepsy - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: